Conference
What does industry think about a “4th hurdle”?
- Date:
- 07 Jul 06
- Venue:
- Budapest, Hungary
- Host:
- European Conference on Health Economics (ECHE)
- Speakers:
- Adrian Towse
- Full Description
- Issues to be discussed:
1. Role of economic evaluation is identifying value in different types of pricing and reimbursement systems. Is reference pricing an alternative to economic assessment? Who sets the price and should there be an explicit willingness to pay for a QALY?
2. Availability of information and handling uncertainty. Payers don’t want to reimburse products that are not cost-effective, but don’t have all of the information at launch. What is an efficient way to resolve this dilemma? How is new information best handled?
3. Coverage of HTA. Is is “all new medicines?” Is that the best use of HTA resources?
4. What is a “good practice” process for an HTA institutional assessment of value? For example, what role do manufacturer’s submissions have? Should there be an appeal process? And patient group involvement?
5. Extent of pan- European sharing of assessments. What is efficient and not efficient? Can Europe’s HTA bodies pool skills and effort or are costs, effectiveness, and willingness to pay too different across European countries?